Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators. San Miguel JF, et al. Among authors: anderson kc. N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479. N Engl J Med. 2008. PMID: 18753647 Free article. Clinical Trial.
NF-kappa B as a therapeutic target in multiple myeloma.
Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. Hideshima T, et al. Among authors: anderson kc. J Biol Chem. 2002 May 10;277(19):16639-47. doi: 10.1074/jbc.M200360200. Epub 2002 Feb 28. J Biol Chem. 2002. PMID: 11872748 Free article.
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC. Richardson PG, et al. Among authors: anderson kc. Blood. 2002 Nov 1;100(9):3063-7. doi: 10.1182/blood-2002-03-0996. Blood. 2002. PMID: 12384400 Free article. Clinical Trial.
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC. Mitsiades N, et al. Among authors: anderson kc. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9. doi: 10.1073/pnas.202445099. Epub 2002 Oct 21. Proc Natl Acad Sci U S A. 2002. PMID: 12391322 Free PMC article.
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC. Mitsiades N, et al. Among authors: anderson kc. Blood. 2003 Mar 15;101(6):2377-80. doi: 10.1182/blood-2002-06-1768. Epub 2002 Nov 7. Blood. 2003. PMID: 12424198 Free article.
Novel biologically based therapies for multiple myeloma.
Munshi NC, Hideshima T, Chauhan D, Richardson P, Anderson KC. Munshi NC, et al. Among authors: anderson kc. Int J Hematol. 2002 Aug;76 Suppl 1:340-1. doi: 10.1007/BF03165281. Int J Hematol. 2002. PMID: 12430878 Review. No abstract available.
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. Richardson PG, et al. Among authors: anderson kc. N Engl J Med. 2003 Jun 26;348(26):2609-17. doi: 10.1056/NEJMoa030288. N Engl J Med. 2003. PMID: 12826635 Free article. Clinical Trial.
1,223 results